TNF and cancer: In a large Phase I study involving histologically confirmed advanced cancer patients, delivering the tumor necrosis factor TNF‐α using the adenoviral vector TNFerade into patient tumors led to objective responses in 43% of patients, with 5 out of 30 patients showing complete response to treatment (Senzer et al., 2004).